⚠ The Tariff Deal and Its Price ConcessionsModerate threat

AbbVie (ABBV) — threat to the moat

AbbVie paid for tariff relief with price concessions whose size it has not disclosed.

In January 2026 AbbVie agreed with the United States government to provide certain pricing concessions and United States research and capital investments in exchange for exemptions from tariffs1. It is a bargain made under pressure: the alternative was tariffs on imported medicines.

Net revenues by region ($M)41,883US 202346,603US 202512,435International 202314,557International 2025AbbVie Form 10-K FY2025
The American business is what the bargain protects.

The concessions narrow the gap between what AbbVie can charge in America and elsewhere, which is where its margins come from. Their size is not broken out in the filings.

The investment commitment, $100 billion over a decade according to the 10-K2, is large against annual capital spending of $1,214 million in 20253. Much of it will be research spending AbbVie would make anyway.

The agreement bought three years of certainty. The 10-K describes an exemption from tariffs in exchange for pricing concessions and investment4. For a company whose products are made partly abroad, a tariff on imported medicines would have raised costs directly; the concessions spread the cost over years instead.

The measure is AbbVie's adjusted gross margin, 84.7% in the second quarter of 20265. A sustained fall would be the first sign the concessions are reaching the income statement.

References
  1. ReportedIn January 2026 AbbVie agreed with the United States government to provide certain pricing concessions and United States research and capital investments in exchange for exemptions from tariffs.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  2. ReportedThe investment commitment, $100 billion over a decade according to the 10-K, is large against annual capital spending of $1,214 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedThe investment commitment, $100 billion over a decade according to the 10-K, is large against annual capital spending of $1,214 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  4. ReportedThe 10-K describes an exemption from tariffs in exchange for pricing concessions and investment.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  5. ReportedThe measure is AbbVie's adjusted gross margin, 84.7% in the second quarter of 2026.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
Sources
Generated September 25, 2026